522 related articles for article (PubMed ID: 29519249)
41. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.
Pinola P; Puukka K; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Lindén Hirschberg A; Ravn P; Skovsager Andersen M; Glintborg D; Mellembakken JR; Ruokonen A; Tapanainen JS; Morin-Papunen LC
Fertil Steril; 2017 Mar; 107(3):788-795.e2. PubMed ID: 28089571
[TBL] [Abstract][Full Text] [Related]
42. Incidence of prediabetes and risk of developing cardiovascular disease in women with polycystic ovary syndrome.
Velija-Asimi Z; Burekovic A; Dujic T; Dizdarevic-Bostandzic A; Semiz S
Bosn J Basic Med Sci; 2016 Nov; 16(4):298-306. PubMed ID: 27648989
[TBL] [Abstract][Full Text] [Related]
43. Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes.
Aziz M; Sidelmann JJ; Faber J; Wissing ML; Naver KV; Mikkelsen AL; Nilas L; Skouby SO
Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1082-9. PubMed ID: 26123797
[TBL] [Abstract][Full Text] [Related]
44. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
[TBL] [Abstract][Full Text] [Related]
45. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
[TBL] [Abstract][Full Text] [Related]
46. Should we individualize lipid profiling in women with polycystic ovary syndrome?
Sundström Poromaa I; Mellembakken JR; Morin-Papunen L; Piltonen T; Puurunen J; Tapanainen JS; Stener-Victorin E; Hirschberg AL; Vanky E; Ravn P; Glintborg D; Andersen M
Hum Reprod; 2016 Dec; 31(12):2791-2795. PubMed ID: 27664213
[TBL] [Abstract][Full Text] [Related]
47. Dyslipidemia involvement in the development of polycystic ovary syndrome.
Liu Q; Xie YJ; Qu LH; Zhang MX; Mo ZC
Taiwan J Obstet Gynecol; 2019 Jul; 58(4):447-453. PubMed ID: 31307731
[TBL] [Abstract][Full Text] [Related]
48. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.
Osibogun O; Ogunmoroti O; Michos ED
Trends Cardiovasc Med; 2020 Oct; 30(7):399-404. PubMed ID: 31519403
[TBL] [Abstract][Full Text] [Related]
49. A visceral adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome.
Ehsani B; Moslehi N; Mirmiran P; Ramezani Tehrani F; Tahmasebinejad Z; Azizi F
Clin Nutr; 2016 Oct; 35(5):1181-7. PubMed ID: 26699405
[TBL] [Abstract][Full Text] [Related]
50. Impact of Polycystic Ovary Syndrome on Silent Coronary Artery Disease and Cardiovascular Events; A Long-term Population-based Cohort Study.
Mahboobifard F; Rahmati M; Niknam A; Rojhani E; Momenan AA; Azizi F; Ramezani Tehrani F
Arch Med Res; 2022 Apr; 53(3):312-322. PubMed ID: 34823887
[TBL] [Abstract][Full Text] [Related]
51. Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study.
Subramanian A; Anand A; Adderley NJ; Okoth K; Toulis KA; Gokhale K; Sainsbury C; O'Reilly MW; Arlt W; Nirantharakumar K
Eur J Endocrinol; 2021 May; 184(5):637-645. PubMed ID: 33635829
[TBL] [Abstract][Full Text] [Related]
52. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study.
Gottschau M; Kjaer SK; Jensen A; Munk C; Mellemkjaer L
Gynecol Oncol; 2015 Jan; 136(1):99-103. PubMed ID: 25451694
[TBL] [Abstract][Full Text] [Related]
53. Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences.
Kousta E; Tolis G; Franks S
Hormones (Athens); 2005; 4(3):133-47. PubMed ID: 16613823
[TBL] [Abstract][Full Text] [Related]
54. Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease.
Guan C; Zahid S; Minhas AS; Ouyang P; Vaught A; Baker VL; Michos ED
Fertil Steril; 2022 May; 117(5):924-935. PubMed ID: 35512976
[TBL] [Abstract][Full Text] [Related]
55. Influence of race/ethnicity on cardiovascular risk factors in polycystic ovary syndrome, the Dallas Heart Study.
Chang AY; Oshiro J; Ayers C; Auchus RJ
Clin Endocrinol (Oxf); 2016 Jul; 85(1):92-9. PubMed ID: 26608823
[TBL] [Abstract][Full Text] [Related]
56. Polycystic ovary syndrome in type 2 diabetes: does it predict a more severe phenotype?
Sim SY; Chin SL; Tan JL; Brown SJ; Cussons AJ; Stuckey BG
Fertil Steril; 2016 Oct; 106(5):1258-1263. PubMed ID: 27456547
[TBL] [Abstract][Full Text] [Related]
57. Self-Reported Polycystic Ovary Syndrome Is Associated With Hypertension: A Northern Finland Birth Cohort 1966 Study.
Ollila ME; Kaikkonen K; Järvelin MR; Huikuri HV; Tapanainen JS; Franks S; Piltonen TT; Morin-Papunen L
J Clin Endocrinol Metab; 2019 Apr; 104(4):1221-1231. PubMed ID: 30445634
[TBL] [Abstract][Full Text] [Related]
58. Diagnosis and management of polycystic ovary syndrome in the UK (2004-2014): a retrospective cohort study.
Ding T; Baio G; Hardiman PJ; Petersen I; Sammon C
BMJ Open; 2016 Jul; 6(7):e012461. PubMed ID: 27401369
[TBL] [Abstract][Full Text] [Related]
59. Screening women with polycystic ovary syndrome for metabolic syndrome.
Dokras A; Bochner M; Hollinrake E; Markham S; Vanvoorhis B; Jagasia DH
Obstet Gynecol; 2005 Jul; 106(1):131-7. PubMed ID: 15994628
[TBL] [Abstract][Full Text] [Related]
60. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis.
Cooney LG; Lee I; Sammel MD; Dokras A
Hum Reprod; 2017 May; 32(5):1075-1091. PubMed ID: 28333286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
